Abstract
Background: Primary chemotherapy as part of multidisciplinary approach is the established treatment for inoperable stage III B breast cancer. The primary endpoints were conversion to operable disease and feasibility of conservative surgery (breast-conserving therapy: BCT); secondary were clinical and pathological complete response rate, local and distant control and safety of the primary regimen. Methods: Between 1998 and 2001, 40 inoperable breast cancer patients ≤60 years, 72% T4abc and 28% T4d, received 6 cycles of primary PEV dose-dense regimen: cisplatin 50 mg/m 2, epirubicin 100 mg/m 2 and vinorelbine 25 mg/m 2, i.v. (q 14). Modified radical mastectomy (MRM) or BCT was performed, followed by adjuvant chemotherapy, radiotherapy and hormone therapy. Results: All patients were converted to operable disease, and BCT was feasible in 24% of T4abc patients. After a median follow-up of 84 months (range 58-96), local and distant relapses were 7.5% (0% in BCT ) and 25% (25% in BCT), respectively. Clinical response was 80% (clinical complete response [cCR]: 20%); pathological complete response (pCR) was 40% in breast, 50% in axilla (pLN0); 32% both in breast and axilla. Neutropenia (G4, 30%), leukopenia (G4, 25%), alopecia (G2, 100%), nausea and vomiting (G4, 20%) were the most common toxicities. Conclusions: The PEV dose-dense regimen seems to be highly effective in terms of resectability and pCR. Toxicity, mainly hematological, was acceptable. Successful BCT is feasible, in selected patients, without compromising local and distant control.
| Original language | English |
|---|---|
| Pages (from-to) | 17-26 |
| Number of pages | 10 |
| Journal | Oncology |
| Volume | 72 |
| Issue number | 1-2 |
| DOIs | |
| Publication status | Published - Nov 2007 |
Fingerprint
Keywords
- Breast cancer
- Breast-conserving therapy
- Dose-dense chemotherapy
- Inoperable T4
- Local-regional relapse rate
- Primary chemotherapy
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer - Long-term results of a phase II trial. / Massidda, Bruno; Atzori, Francesco; Scanu, Antioco; Contu, Antonio; Farris, Antonio; Catino, Anna Maria; Palmeri, Sergio; Minerba, Luigi; Ionta, Maria Teresa.
In: Oncology, Vol. 72, No. 1-2, 11.2007, p. 17-26.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dose-dense primary chemotherapy, as part of multidisciplinary treatment, for inoperable stage III B breast cancer - Long-term results of a phase II trial
AU - Massidda, Bruno
AU - Atzori, Francesco
AU - Scanu, Antioco
AU - Contu, Antonio
AU - Farris, Antonio
AU - Catino, Anna Maria
AU - Palmeri, Sergio
AU - Minerba, Luigi
AU - Ionta, Maria Teresa
PY - 2007/11
Y1 - 2007/11
N2 - Background: Primary chemotherapy as part of multidisciplinary approach is the established treatment for inoperable stage III B breast cancer. The primary endpoints were conversion to operable disease and feasibility of conservative surgery (breast-conserving therapy: BCT); secondary were clinical and pathological complete response rate, local and distant control and safety of the primary regimen. Methods: Between 1998 and 2001, 40 inoperable breast cancer patients ≤60 years, 72% T4abc and 28% T4d, received 6 cycles of primary PEV dose-dense regimen: cisplatin 50 mg/m 2, epirubicin 100 mg/m 2 and vinorelbine 25 mg/m 2, i.v. (q 14). Modified radical mastectomy (MRM) or BCT was performed, followed by adjuvant chemotherapy, radiotherapy and hormone therapy. Results: All patients were converted to operable disease, and BCT was feasible in 24% of T4abc patients. After a median follow-up of 84 months (range 58-96), local and distant relapses were 7.5% (0% in BCT ) and 25% (25% in BCT), respectively. Clinical response was 80% (clinical complete response [cCR]: 20%); pathological complete response (pCR) was 40% in breast, 50% in axilla (pLN0); 32% both in breast and axilla. Neutropenia (G4, 30%), leukopenia (G4, 25%), alopecia (G2, 100%), nausea and vomiting (G4, 20%) were the most common toxicities. Conclusions: The PEV dose-dense regimen seems to be highly effective in terms of resectability and pCR. Toxicity, mainly hematological, was acceptable. Successful BCT is feasible, in selected patients, without compromising local and distant control.
AB - Background: Primary chemotherapy as part of multidisciplinary approach is the established treatment for inoperable stage III B breast cancer. The primary endpoints were conversion to operable disease and feasibility of conservative surgery (breast-conserving therapy: BCT); secondary were clinical and pathological complete response rate, local and distant control and safety of the primary regimen. Methods: Between 1998 and 2001, 40 inoperable breast cancer patients ≤60 years, 72% T4abc and 28% T4d, received 6 cycles of primary PEV dose-dense regimen: cisplatin 50 mg/m 2, epirubicin 100 mg/m 2 and vinorelbine 25 mg/m 2, i.v. (q 14). Modified radical mastectomy (MRM) or BCT was performed, followed by adjuvant chemotherapy, radiotherapy and hormone therapy. Results: All patients were converted to operable disease, and BCT was feasible in 24% of T4abc patients. After a median follow-up of 84 months (range 58-96), local and distant relapses were 7.5% (0% in BCT ) and 25% (25% in BCT), respectively. Clinical response was 80% (clinical complete response [cCR]: 20%); pathological complete response (pCR) was 40% in breast, 50% in axilla (pLN0); 32% both in breast and axilla. Neutropenia (G4, 30%), leukopenia (G4, 25%), alopecia (G2, 100%), nausea and vomiting (G4, 20%) were the most common toxicities. Conclusions: The PEV dose-dense regimen seems to be highly effective in terms of resectability and pCR. Toxicity, mainly hematological, was acceptable. Successful BCT is feasible, in selected patients, without compromising local and distant control.
KW - Breast cancer
KW - Breast-conserving therapy
KW - Dose-dense chemotherapy
KW - Inoperable T4
KW - Local-regional relapse rate
KW - Primary chemotherapy
UR - http://www.scopus.com/inward/record.url?scp=37049026000&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37049026000&partnerID=8YFLogxK
U2 - 10.1159/000111084
DO - 10.1159/000111084
M3 - Article
C2 - 17998786
AN - SCOPUS:37049026000
VL - 72
SP - 17
EP - 26
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 1-2
ER -